Canagliflozin Suppresses Atrial Remodeling in a Canine Atrial Fibrillation Model.
Animals
Atrial Fibrillation
/ metabolism
Atrial Remodeling
/ drug effects
Canagliflozin
/ pharmacology
Dogs
Electrophysiologic Techniques, Cardiac
/ methods
Heart Atria
/ pathology
Heart Conduction System
/ metabolism
Oxidative Stress
/ drug effects
Reactive Oxygen Species
/ analysis
Sodium-Glucose Transporter 2
/ metabolism
Sodium-Glucose Transporter 2 Inhibitors
/ pharmacology
Treatment Outcome
atrial fibrillation
atrial remodeling
canagliflozin
oxidative stress
sodium–glucose cotransporter 2 inhibitor
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
19 01 2021
19 01 2021
Historique:
pubmed:
6
1
2021
medline:
15
10
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
Background Recent clinical trials have demonstrated the possible pleiotropic effects of SGLT2 (sodium-glucose cotransporter 2) inhibitors in clinical cardiovascular diseases. Atrial electrical and structural remodeling is important as an atrial fibrillation (AF) substrate. Methods and Results The present study assessed the effect of canagliflozin (CAN), an SGLT2 inhibitor, on atrial remodeling in a canine AF model. The study included 12 beagle dogs, with 10 receiving continuous rapid atrial pacing and 2 acting as the nonpacing group. The 10 dogs that received continuous rapid atrial pacing for 3 weeks were subdivided as follows: pacing control group (n=5) and pacing+CAN (3 mg/kg per day) group (n=5). The atrial effective refractory period, conduction velocity, and AF inducibility were evaluated weekly through atrial epicardial wires. After the protocol, atrial tissues were sampled for histological examination. The degree of reactive oxygen species expression was evaluated by dihydroethidium staining. The atrial effective refractory period reduction was smaller (
Identifiants
pubmed: 33399004
doi: 10.1161/JAHA.119.017483
pmc: PMC7955321
doi:
Substances chimiques
Reactive Oxygen Species
0
Sodium-Glucose Transporter 2
0
Sodium-Glucose Transporter 2 Inhibitors
0
Canagliflozin
0SAC974Z85
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e017483Références
Cardiovasc Res. 2017 Dec 1;113(14):1743-1752
pubmed: 29016722
Europace. 2012 Aug;14(8):1206-14
pubmed: 22454409
Int J Cardiol. 2007 Feb 7;115(2):135-43
pubmed: 16764958
Am J Physiol Heart Circ Physiol. 2013 Apr 15;304(8):H1060-76
pubmed: 23396451
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Circulation. 2001 Jul 10;104(2):174-80
pubmed: 11447082
Circulation. 2011 Sep 6;124(10):1107-17
pubmed: 21844076
Heart Vessels. 2017 Jan;32(1):90-100
pubmed: 27401739
J Cardiovasc Electrophysiol. 2001 Feb;12(2):183-4
pubmed: 11232617
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
J Am Heart Assoc. 2021 Jan 19;10(2):e017483
pubmed: 33399004
Antioxid Redox Signal. 2014 Mar 10;20(8):1268-85
pubmed: 23924190
Circulation. 2016 Feb 23;133(8):698-705
pubmed: 26819376
Heart. 2012 Jul;98(14):1063-6
pubmed: 22628539
Circulation. 1995 Oct 1;92(7):1954-68
pubmed: 7671380
Circulation. 2016 Feb 23;133(8):706-16
pubmed: 26819374
Heart Vessels. 2018 Oct;33(10):1258-1265
pubmed: 29721673
Biochim Biophys Acta. 2015 May;1852(5):805-15
pubmed: 25615792
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
Sci Rep. 2015 Jul 14;5:11427
pubmed: 26169582
Diabetes Care. 2016 Jul;39(7):1108-14
pubmed: 27289126
Science. 2013 Jan 11;339(6116):211-4
pubmed: 23223453
Cardiovasc Diagn Ther. 2014 Feb;4(1):28-35
pubmed: 24649422
Diabetes Care. 2016 Jul;39(7):1115-22
pubmed: 27289124
J Diabetes Investig. 2019 Jul;10(4):933-946
pubmed: 30663266
J Endocrinol. 2018 Feb;236(2):69-84
pubmed: 29142025
Free Radic Biol Med. 2003 Nov 15;35(10):1310-8
pubmed: 14607530
Circ J. 2008 Feb;72(2):318-26
pubmed: 18219173